Navigation Links
Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
Date:7/31/2012

SAN DIEGO, July 31, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, will announce financial results for the second quarter ended June 30, 2012 on Tuesday, August 7, 2012 before the markets open. The announcement will be followed by a live webcast and conference call at 8:30 a.m. Eastern time (5:30 a.m. Pacific time).

Orexigen management will host the call and webcast to discuss financial results and recent business highlights. The live call may be accessed by phone by calling (888) 771-4371 (domestic) or (847) 585-4405 (international), participant code 33012560. The webcast can be accessed live on the investor relations section of the Orexigen web site at www.orexigen.com and will be archived for 14 days following the call.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase II clinical trials. Further information about the Company can be found at www.orexigen.com.

McDavid Stilwell
Vice President, Corporate Communications & Business Development
858-875-8600

 


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
6. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
7. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
8. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
9. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
10. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
11. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ... stock of Solta Medical, Inc. (NASDAQ: SLTM ...
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... results for the fourth quarter of 2013 on Monday, February ... for release after the close of trading. ... conference call to discuss the operating highlights and financial results ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... (NYSE: DHR ) announced today that Henk ... and Amir Aghdaei and Henrik Roos have each been ... In his new role, Henk van Duijnhoven will ... Group and Sybron Dental Specialties.  Danaher,s Dental segment generated ...
... ALISO VIEJO, Calif., April 5, 2011 Avanir Pharmaceuticals, Inc. ... will present an overview of the company at the Future Leaders ... Location: Millennium Broadway Hotel & Conference Center, New York, ... Presentation time: 2:00pm ET A live ...
Cached Medicine Technology:Danaher Announces Executive Appointments 2
(Date:4/22/2014)... patients diagnosed with non-small cell lung cancer are 70 ... percentage, these elderly patients are not well represented in ... made it difficult to reach evidence based clinical recommendations. ... Task Force and Lung Cancer Group along with the ... opinion on managing treatment for elderly patients with non-small ...
(Date:4/22/2014)... trauma, illness, alcohol or other drug abuse, these stressors ... that can go awry and activate conditions such as ... , Until now, it has been unclear how much ... brain. Past studies have shown that when an expectant ... she experiences some trauma or illness, her baby may ...
(Date:4/22/2014)... intervention researchers have been informed that the National Institute ... Institutes of Health, will award an $8 million grant ... an experimental drug for stroke. , The drug, ... plasminogen activator, or rtPA the "clot-busting" drug currently ... laboratory rodent studies, 3K3A-APC, used in combination with rtPA, ...
(Date:4/22/2014)... a clinical trial led by Dana-Farber Cancer Institute ... approved a molecularly targeted drug as second-line treatment ... standard chemotherapy has failed. , The FDA approval ... manufacturer, Lilly Oncology, of Indianapolis. A monoclonal antibody ... sold under the name Cyramza, and is the ...
(Date:4/22/2014)... the University of Calgary,s Hotchkiss Brain Institute (HBI) uncovers ... as a means to restore connections after injury. Dr. ... molecule that directly regulates nerve cell growth in the ... prestigious journal Nature Communications , with lead authors ... made the surprising discovery that a protein called Retinoblastoma ...
Breaking Medicine News(10 mins):Health News:EORTC and SIOG update expert opinion on management of elderly patients with NSCLC 2Health News:Life stressors trigger neurological disorders, researchers find 2Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 2Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 3Health News:FDA approves first targeted drug for advanced stomach cancer 2Health News:Scientists discover a new way to enhance nerve growth following injury 2
... , ... ... ... ...
... ... ... ... ...
... sheds light on brain mechanism related to processing images , ... recognizing faces may be relieved to know that the problem ... could be in their genes, new research suggests. , The ... genes) and 125 non-identical, same-sex twins (who share 50 percent ...
... C. Bray of the University of Calgary was recently ... for Sports Medicine,s (AOSSM) $250,000 Ligament and Tendon Repair ... Ligament and Tendon Healing: Role of Neuropeptides." ... of Calgary, and Per Renstrom and Paul Ackermann, both ...
... mechanisms of transport have important applicationstransport of nutrients ... aeration of agricultural soils, performance of chemical reactors, ... and the design of clay membranes for retaining ... has important roles in biology, physics, and chemistry, ...
... ... depression and stress with amazing technology; free assessments offered in March. , ... Arlington, TX (Vocus) February 24, 2010 -- The ... trigger anxiety, loneliness, depression and even thoughts of suicide. At New Life Brain Center™, ...
Cached Medicine News:Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 2Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 3Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 4Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 5Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 6Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 7Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 8Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 9Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 10Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 11Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 12Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 13Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 14Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 15Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 16Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 17Health News:ProAssurance Reports Year-End and Fourth Quarter 2009 Results 18Health News:Soyfoods Aid Those With Lactose Intolerance 2Health News:Soyfoods Aid Those With Lactose Intolerance 3Health News:Soyfoods Aid Those With Lactose Intolerance 4Health News:Soyfoods Aid Those With Lactose Intolerance 5Health News:Trouble Recognizing Faces Could Be Genetic 2Health News:$250,000 grant awarded for groundbreaking ligament and tendon repair research 2Health News:Where does the fluid go? 2Health News:Brain Balancing Gives Hope for Sufferers of Depression, Stress, and Insomnia at New Life Brain Center, 2Health News:Brain Balancing Gives Hope for Sufferers of Depression, Stress, and Insomnia at New Life Brain Center, 3
Complete Cataract Competence , OPMI VISU 140 is compact, good and economical. It's everything a cataract specialist needs today....
BD Vacutainer® Specialty Tubes - Acid Citrate Dextrose (ACD)...
... BD Vacutainer® SST™ Tubes ... a polymer gel for ... used for serum determinations ... provide an efficient means ...
MONOJECT Red/Yellow Mottled Stopper...
Medicine Products: